Journal of Infection and Public Health, 2015 Summary: This paper reviews the current literature and information on the combination drug Complera™ (rilpivirine/emtricitabine/tenofovir disoproxil fumarate) that was approved by the Food and Drug Administration (FDA) in August 2011.PubMed, Cochrane and
Wissam K. Kabbara, Wijdan H. Ramadan
doaj +2 more sources
Minimal impact of pregnancy on rilpivirine pharmacokinetics in women living with HIV
International Journal of Infectious DiseasesObjectives: Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for preventing mother-to-child HIV transmission, may have reduced plasma exposure in the second and third trimesters due to increased metabolism/elimination in pregnant women ...
Benjamin Kably +9 more
doaj +2 more sources
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings [PDF]
HIV/AIDS: Research and Palliative Care, 2011 Nathan Ford1,2, Janice Lee1, Isabelle Andrieux-Meyer1, Alexandra Calmy1,31Médecins Sans Frontières, Geneva, Switzerland; 2Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa ...
Ford N, Lee J, Andrieux-Meyer I, Calmy A
doaj +3 more sources
A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants [PDF]
Retrovirology, 2012 Background The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis.
Johnson Barry C +11 more
doaj +2 more sources
Long-Acting Therapeutics in Pediatric Health: Bridging Innovation and Access. [PDF]
Clin Pharmacol TherChildren have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Venkatasubramanian P +5 more
europepmc +2 more sources
Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology
, 2023 Rilpivirine is an antiretroviral drug used to treat AIDS worldwide. The drug is a non-nucleoside reverse transcriptase inhibitor that halts the cDNA elongation process and, thus, the capacity of the HIV-1 virus to replicate.
Mariana Pereira, Nuno Vale
core +1 more source
Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro [PDF]
, 2013 Rilpivirine is a nonnucleoside reverse transcriptase inhibitor approved for treatment of HIV-1 infection in antiretroviral-naive adult patients. Potential interactions with drug transporters have not been fully investigated.
core +1 more source
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults [PDF]
, 2015 We characterized transmitted drug resistance to rilpivirine and the predicted efficacy of first-line rilpivirine-containing regimens in antiretroviral-naive Spanish patients.
Rodriguez, C. +11 more
core +1 more source
Viruses, 2022 Two-drug regimens (2DRs) are emerging in clinical practice guidelines as treatment option for both naive and treatment-experienced people living with HIV (PLHIV).
Carmen Hidalgo-Tenorio +8 more
doaj +1 more source
Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis [PDF]
Sexually Transmitted Infections, 2021 ObjectiveTo assess the risk of neuropsychiatric adverse effects (ie, depression, anxiety, insomnia, dizziness, suicidal behaviour) among patients treated with rilpivirine, dolutegravir and dolutegravir/rilpivirine.DesignThis is a systematic review and meta-analysis of randomised controlled trials.
Anthony Allen Reeves +5 more
openaire +2 more sources